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AbstrAct
Lactic acid generated by highly glycolytic tumours is exported by the 
MonoCarboxylate Transporters, MCT1 and MCT4, to maintain pHi and energy 
homeostasis. We report that MCT1 inhibition combined with Mct4 gene disruption 
severely reduced glycolysis and tumour growth without affecting ATP levels. Because 
of the key role of the 5’-AMP-activated protein kinase (AMPK) in energy homeostasis, 
we hypothesized that targeting glycolysis (MCT-blockade) in AMPK-null (Ampk-/-) 
cells should kill tumour cells from ‘ATP crisis’. We show that Ampk-/--Ras-transformed 
mouse embryonic fibroblasts (MEFs) maintained ATP levels and viability when 
glycolysis was inhibited. In MCT-inhibited MEFs treated with OXPHOS inhibitors the 
ATP level and viability collapsed in both Ampk+/+ and Ampk-/- cells. We therefore 
propose that the intracellular acidification resulting from lactic acid sequestration 
mimicks AMPK by blocking mTORC1, a major component of an ATP consuming 
pathway, thereby preventing ‘ATP crisis’. Finally we showed that genetic disruption 
of Mct4 and/or Ampk dramatically reduced tumourigenicity in a xenograft mouse 
model suggesting a crucial role for these two actors in establishment of tumours in a 
nutrient-deprived environment. These findings demonstrated that blockade of lactate 
transport is an efficient anti-cancer strategy that highlights the potential in targeting 
Mct4 in a context of impaired AMPK activity.
INtrODUctION
Dividing cancer cells rely extensively on glycolysis 
to maintain a high rate of proliferation [1-3]. Despite a 
lower yield of ATP than that of oxidative phosphorylation 
(OXPHOS), glycolysis generates precursors for the 
synthesis of nucleotides, amino acids, and membrane 
lipids [4]. Although exacerbated glycolysis is a common 
feature of any proliferative cell, genetic lesions driving 
cancer progression have a major impact on metabolism 
and promote glycolysis [5]. The dependency of cancer 
cells on glycolysis is amplified during tumour growth. Part 
of the tumour encounters an avascular microenvironment 
deficient in oxygen, i.e. hypoxic, as a consequence of rapid 
proliferation of cancer cells and aberrant neovasculature 
[6]. The transcription factor the Hypoxia-Inducible Factor 
1 (HIF-1) [7], a key actor in cellular adaptation to hypoxia, 
induces a major shift in cellular metabolism toward 
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glycolysis [6, 8, 9]. HIF-1, through the transcriptional 
upregulation of almost all the glycolytic enzymes together 
with inhibition of mitochondrial pyruvate dehydrogenase 
[10], creates an addiction to glycolysis of hypoxic tumour 
cells, which produce biomass as long as the major 
nutrients such as glucose are not depleted. So inhibition 
of glycolysis appears to be a promising avenue for the 
development of anti-tumour targeted therapies [11-15].
As a consequence of exacerbated glycolysis large 
amounts of lactic acid are produced. Our laboratory has 
been evaluating the anti-cancer approach of inhibiting 
lactic acid export. This approach leaded to intracellular 
accumulation of lactic acid associated with a severe drop 
in the intracellular pH (pHi), which results in inhibition of 
glycolysis [16, 17]. Lactate transport is carried out by four 
members of the monocarcarboxylate transporter (MCT) 
family (MCT1-4) [18], which have received revived 
attention in the context of cancer [19, 20]. They are H+/
lactate bidirectional symporters with different affinities 
and tissue distribution. MCT1 is ubiquitous, whereas 
MCT4, a HIF-1-target gene [21], is strongly expressed 
in glycolytic tissues [22-24]. We and others showed that 
inhibition of MCTs or genetic disruption of MCT/basigin 
complexes leaded to a blockade in lactate transport and 
had anti-proliferative effects by reducing the glycolytic 
flux [15, 17, 25, 26]. However, although this approach 
severely restricted tumour growth it did not affect cancer 
cell viability unless the mitochondrial complex I was 
inhibited by biguanides [17, 25-27]. The major cause of 
resistance to cell death by inhibition of energy-producing 
pathways resides in the metabolic plasticity governed by 
the central guardian of the cellular ATP level, the AMP-
activated protein kinase (AMPK) [2, 16, 27, 28]. AMPK 
is a highly conserved serine/threonine protein kinase 
involved in the control of energy homeostasis [28]. AMPK 
exists as a heterotrimeric protein comprising a catalytic α 
subunit and regulatory β/γ subunits. As a direct sensor of 
the AMP:ATP ratio, AMPK is rapidly activated by stresses 
that cause a reduction in ATP levels, such as glucose 
starvation [29], metabolic inhibitors [30], or muscle 
contraction [31, 32]. When activated, AMPK maintains 
a viable level of ATP, accelerating energy production, 
through increased glucose uptake [33], glycolysis [34], 
mitochondrial biogenesis [35], and mitophagy [36], 
while switching off energy consuming processes such 
as synthesis of proteins [37-40], glycogen[41] and fatty 
acids [42, 43]. However, although extensively studied, the 
regulation and function of AMPK remain only partially 
understood, especially in cancer.
We therefore hypothesized that genetic disruption 
of AMPK in a context of strong inhibition of glycolysis 
(MCT blockade) should sensitize tumour cells to death 
as a result of a deficit in maintenance of the ATP level. 
As no specific inhibitor for AMPK exists, a model of 
Ras-transformed murine embryonic fibroblasts (MEFs) 
genetically knocked out for the two catalytic subunits 
of AMPK (Ampk-/-), Ampkα1 and Ampk2 [44], was used. 
We first demonstrated that pharmacological inhibition of 
MCT1 combined with genetic knockout of Mct4 (Mct4-/-) 
in Ras-transformed MEFs, lead to inhibition of glycolysis 
and proliferation in vitro. However, Ampk-/- MEFs 
preserved viable levels of ATP following acute inhibition 
of glycolysis. Moreover, AMPK was not capable of 
providing a survival advantage following severe inhibition 
of ATP production by glycolysis and OXPHOS. This 
unexpected finding suggested that AMPK is dispensable 
in regulating the plasticity of bioenergetic pathways. 
Finally we showed, using a xenograft tumour model, that 
the knockout of Ampk or Mct4 (Ampk-/- or Mct4-/-) delayed 
tumour development while Ampk-/- Mct4-/- MEFs severely 
impacted on tumour establishment. These in vivo studies 
suggest that combined inhibition of AMPK and MCT4 
could be exploited as an anti-cancer strategy.
rEsULts
In the absence of an energy stress, genetic 
disruption of AMPK in MEFs does not affect 
glycolysis, OXPHOs or cell proliferation
Wild-type murine embryonic fibroblasts (MEFs) 
(Ampk+/+) or deficient for the expression of both the 
AMPKα1 and AMPKα2 catalytic subunits (Ampk-/-) 
were transformed with oncogenic RasV12 (Figure 1a). 
Transformation did not change the ability of AMPK to 
be activated in the absence of glucose and to activate 
Acetyl-CoA carboxylase (P-ACC), one of the main targets 
of AMPK (Figure 1b). We sought to determine whether 
the lack of functional AMPK affected metabolism, ATP 
levels and cell proliferation. The oxygen consumption rate 
(OCR) showed no significant difference between Ampk+/+ 
and Ampk-/- MEFs (Figure 1c). Oligomycin (Oligo), an 
inhibitor of the F0F1-ATP synthase, reduced the OCR to 
a similarly to that of AMPK in Ampk+/+ or Ampk-/- MEFs 
suggesting that absence of AMPK did not modify the 
amount of ATP produced by mitochondrial respiration. 
The extracellular acidification rate (ECAR), the index of 
lactic acid export and thus glycolysis, was also identical 
in cells with and without functional AMPK, in the 
absence or presence of glucose (Figure 1d). Inhibition 
of mitochondrial ATP synthesis by oligomycin was 
responsible for a rapid shift toward glycolysis metabolism, 
independently of AMPK. Similarly, no significant 
difference in the ATP level was observed in optimal 
conditions of cell growth (Figure 1e). Finally, Ampk+/+ 
and Ampk-/- MEFs proliferated in vitro in normoxia or 
hypoxia in the presence of 25mM glucose (Figure 1f and 
1g). However, Ampk-/- MEFs proliferated slightly less 
rapidly in hypoxia. Taken together, these results suggest 
that AMPK is dispensable under conditions of plentiful 
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Figure 1: Metabolic characterization in vitro of rasV12-transformed mouse embryonic fibroblasts (MEFs) expressing 
(Ampk+/+) or not (Ampk-/-) Ampk. (a) Cell lysates of Ampk+/+ and Ampk-/- MEFs not transformed (-) or transformed (+) by RasV12 were 
analyzed by immunoblotting for Ras. (b) Cell lysates of Ampk+/+ and Ampk-/- MEFs transformed by RasV12 were analyzed by immunoblotting 
for phosphorylation of AMPK (Thr172) and ACC Ser79 after 1h of glucose starvation. (c) Oxygen consumption rate (OCR) was measured 
in real time with a Seahorse XF for Ampk+/+ (Ampk+/+) and Ampk-/- (Ampk-/-) MEFs transformed by RasV12 in normoxia. Glucose (10 mM), 
oligomycin (Oligo 1 µM), carbonilcyanide p-triflouromethoxyphenylhydrazone (FCCP 1µM) and rotenone/antimycine A (Rot/AA 1 µM) 
were injected at the indicated times. Mean±S.E.M. is representative of three independent experiments carried out in quadruplicate. (d) 
Extracellular acidification rate (ECAR) of normoxic Ampk+/+ (Ampk+/+) and Ampk-/- (Ampk-/-) MEFs transformed by RasV12 were evaluated 
with a Seahorse XF. Glucose (10 mM) and oligomycin (Oligo 1 µM) were injected at the indicated times. The mean±S.E.M. is representative 
of three independent experiments carried out in quadruplicate. (e) The total cellular ATP levels in cells incubated in normoxia for 48 h 
were standardized to protein content for each condition. The mean±S.E.M. is representative of three independent experiments carried out 
in quadruplicate. Non significative (n.s.). (f) In vitro proliferation of Ampk+/+ (Ampk+/+) and Ampk-/- (Ampk-/-) MEFs transformed by RasV12 
incubated in normoxia (Nx) or in hypoxia 1% O2 (Hx) up to 96 h. The mean±S.E.M. is representative of three independent experiments 
carried out in duplicate. (g) Clonal growth in normoxia (Nx) or hypoxia 1% O2 (Hx) of Ampk+/+ (Ampk+/+) and Ampk-/- (Ampk-/) MEFs 
transformed by RasV12 for 8 days before staining and visualization of the colonies. 
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nutrients, either in normoxia or hypoxia.
combined inhibition of Mct1 and Mct4 
blocked the export of lactate and inhibited 
glycolysis independently of AMPK
To inhibit glycolysis, we blocked the output 
of cellular lactate by modulating the expression and/
or activity of MCT1 and 4. MCT1 was expressed in 
normoxia (Figure 2a). While MCT1 is not a transcriptional 
target of HIF-1, we observed that its expression was 
three-fold higher (3.3±0.5) in hypoxia whereas the level 
of expression of the mRNA was not modified (data not 
shown). However, protein expression of MCT4 was 
undetectable in normoxia, but was strongly induced in 
hypoxia (Figure 2a). MCT4 expression was higher in 
Ampk-/- MEFs than in Ampk+/+ MEFS in hypoxia. Since 
no specific inhibitor of MCT4 is available, we knocked 
out the Mct4 gene (Mct4-/-) in Ampk+/+ and Ampk-/- MEFs. 
Knockout did not alter expression of MCT1 (Figure 2a). 
Genetic knockout of Mct4 in Ampk+/+ and Ampk-/- MEFs 
did not alter lactate transport in hypoxia (Figure 2b), 
suggesting that MCT1 could compensate fully for the 
lack of MCT4 expression. Pharmacological inhibition 
of MCT1 (MCTi) in cells lacking MCT4 (Ampk+/+ Mct4-
/- and Ampk-/- Mct4-/- MEFs) abolished lactate transport in 
hypoxia (Figure 2b and Supplementary Figure 1a) and thus 
leaded to its intracellular accumulation in Ampk+/+ Mct4-
/- MEFs (Figure 2c) and Ampk-/- Mct4-/- MEFs (Figure 2d 
and Supplementary Figure 1b). However, Mct4 knockout 
reduced the glycolytic flux of Ampk+/+cells compared to 
Ampk-/- MEFs (Figure 2e). Inhibition of MCT1 in Mct4-
/- MEFs dramatically reduced the glycolytic flux in the 
presence or absence of functional AMPK in normoxia 
(Figure 2e and Supplementary Figure 1c). Inhibition 
of glycolysis was not associated with an increase in 
mitochondrial respiration (Supplementary Figure 1d 
and 1e). We also observed that consumption of glucose 
(Supplementary Figure 2a) and lactate secretion in the 
extracellular medium (Supplementary Figure 2b) were 
both affected by combined inhibition of MCT1 and MCT4 
in Ampk+/+ ou Ampk-/- MEFs, in normoxia and hypoxia, 
confirming a decrease in the glycolytic flux in response 
to inhibition of MCTs. Finally, AMPK was activated in 
response to MCT inhibition in Ampk+/+ Mct4-/- MEFs 
(Figure 2f and Supplementary Figure 2c), as shown by the 
active phosphorylation at Thr172 of the AMPKα subunit 
(P-AMPK) and of ACC. Colon adenocarcinoma LS174 
cells were used to verify that activation was not only 
specific to MEFs but also found in a model of glycolytic 
tumour cells. We demonstrated that AMPK activation 
was faster in LS174 cells in response to inhibition of 
MCTs (Supplementary Figure 2d). AMPK and ACC 
phosphorylation occured after 15min, was maintained 
over time and required combined inhibition of MCT1 
and MCT4 (Supplementary Figure 2e). Activation was 
probably due to the stress in energy generated by inhibition 
of glycolysis, as recently reported in LS174 cells [17].
Although slight differences were observed between 
Ampk+/+ and Ampk-/- MEFs (Figure 2a, 2b and 2e), 
together these results show that inhibition of MCTs lead 
to intracellular accumulation of lactate and a dramatic 
reduction in the glycolytic flux in MEFs with and without 
functional AMPK.
AMPK is not required for maintenance of a viable 
AtP level following blockade in glycolysis
We then looked at the impact of blocking glycolysis 
on ATP levels in the absence of AMPK. We analyzed 
the levels of ATP in Ampk+/+ and Ampk-/- MEFs, in the 
presence (Mct4+/+) or the absence (Mct4-/-) of MCT4, 
and after addition or not of MCTi (Figure 3a and 
Supplementary Figure 3a). In control MEFs (Ampk+/+ 
Mct4+/+), we observed that the ATP level increased 
slightly and reproducibly, although not significantly, after 
48h of MCTi treatment in normoxia. As we previously 
observed, using different cell lines [45, 46], 48h of 
hypoxia significantly increased ATP levels (25%±5%) 
compare to the levels in normoxia. Inhibition of MCT1 
also showed a slight tendency to increase the ATP level in 
cells expressing MCT4 in hypoxia. Knockout of Mct4 in 
Ampk+/+ MEFs increased basal levels of ATP in normoxia 
and hypoxia, probably due to inhibition of proliferation. 
MCT1 inhibition in Ampk+/+Mct4-/- MEFs reduced the 
ATP level in normoxia and hypoxia by about 23%±3% 
and 47%±3%, respectively. The most important effect 
of MCT inhibition in hypoxia was due mostly to the 
metabolic shift toward glycolysis, which made the cells 
more dependent on this pathway for ATP production [15-
17]. The basal level of ATP of Ampk-/- MEFs in normoxia 
was similar to that of Ampk+/+ MEFs but not modified by 
inhibiting MCT1 or by hypoxia. Similar to Ampk+/+ Mct4-
/- MEFs, Mct4 knockout in Ampk-/- MEFs (Ampk-/- Mct4-/-) 
increased the basal level of ATP. However, cells were more 
sensititive to MCT1 inhibition. Indeed, the level of ATP 
was reduced by about 16%±3% in normoxia and 28%±3% 
in hypoxia for the first clone (Figure 3a) and 14%±5% 
in normoxia and 29%±3% in hypoxia for the second 
independent clone (Supplementary Figure 3a). In the 
presence of MCTi in normoxia or hypoxia, decreases in 
ATP levels did not correlate with a significant increase in 
cell death in Ampk+/+ Mct4-/- or Ampk-/- Mct4-/- MEFs over 
a short period of time (8 and 2h, data not shown) or 48h 
(Figure 3b and Supplementary Figure 3b). We examined 
the ability of Ampk-/- (Figure 3c, right panels) to grow in 
the presence or the absence of MCT4 in normoxia (top 
panels) or hypoxia (Figure 3c, bottom panels) compared 
to Ampk+/+ MEFs (Figure 3c, left panels). In normoxia, the 
addition of MCTi did not alter the proliferation of MEFs 
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Figure 2: The MCT1 pharmacological inhibitor (MCTi) reduced lactate transport and the glycolytic rate in Ampk+/+ 
and Ampk-/- MEFs. (a) Cell lysates of Ampk+/+ (Ampk+/+) and Ampk-/- MEFs (Ampk-/-) expressing (Mct4+/+) or not (Mct4-/-) MCT4 
incubated in normoxia (Nx) or hypoxia 1% O2 (Hx). Whole-cell lysates were analyzed by immunoblotting for HIF-1α, MCT4, and MCT1. 
Detection of HSP90 was used as a loading control. (b) Lactate uptake in Ampk+/+ (Ampk+/+, black bars) and Ampk-/- (Ampk-/-, grey bars) 
MEFs expressing (Mct4+/+) or not (Mct4-/-) MCT4 in the absence (total uptake, filled bars) or presence of 300 nM MCTi (MCTi, hatched 
bars) in hypoxia 1% O2 (Hx) for 48 h. Uptake was conducted as 3-min time-points in duplicate. The mean±S.E.M. is representative of 
two independent experiments carried out in duplicate. * p < 0.005, ** p <  0.001. (c) Time-course of intracellular lactate concentration in 
response to glucose addition (25 mM) to Ampk+/+ (Ampk+/+) MEF expressing (Mct4+/+) or not (Mct4-/-) MCT4 in the presence of DMSO (solid 
line) or MCTi (300 nM, dotted line) in hypoxia 1% O2 (Hx). The mean±S.E.M. is representative of three independent experiments carried 
out in triplicate. (d) Time-course of intracellular lactate concentration in response to glucose addition (25mM) to Ampk-/- MEFs expressing 
(Mct4+/+) or not (Mct4-/-) MCT4 in the presence of DMSO (solid line) or MCTi (300 nM, dotted line). The mean±S.E.M. is representative 
of three independent experiments carried out in triplicate. (e) The extracellular acidification rate (ECAR) of Ampk+/+ (Ampk+/+, black bars) 
and Ampk-/- MEFs (Ampk-/-, grey bars) expressing (Mct4+/+) or not (Mct4-/-) MCT4 with DMSO (filled bars) or MCTi (300nM, signs in 
bars) in normoxia (Nx) were evaluated after injection of glucose (10 mM) with a Seahorse XF. The mean±S.E.M. is representative of three 
independent experiments carried out in quadruplicate. * p < 0.005, ** p < 0.001. (f) Cell lysates of Ampk+/+ (Ampk+/+) and Ampk-/- (Ampk-/-) 
MEFs expressing (Mct4+/+) or not (Mct4-/-) MCT4 in normoxia (Nx) in the absence (-) or presence (+) of 300nM MCTi were analyzed by 
immunoblotting for Phospho-AMPK (P-AMPK), and Phospho-ACC (P-ACC). Detection of HSP90 was used as a loading control.
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Figure 3: Pharmacological inhibition of MCT1 (MCTi) in combination with knockout of Mct4 (Ampk+/+Mct4-/- and 
Ampk-/-Mct4-/- MEFs) decreased the AtP level and the proliferation independently of the presence or absence of AMPK 
but did not alter cellular viability. (a) Total cellular ATP level in Ampk+/+ (Ampk+/+) and Ampk-/- (Ampk-/-) MEFs expressing (Mct4+/+) 
or not (Mct4-/-) MCT4 incubated in normoxia (Nx) or in hypoxia 1% O2 (Hx) for 48 h in the absence (DMSO) or presence (+ MCTi, 
300 nM) of MCTi. ATP levels were measured in whole-cell lysates and standardized to the cell protein content for each condition. The 
mean±S.E.M. is representative of three independent experiments carried out in triplicate. The mean±S.E.M. is representative of three 
independent experiments carried out in quadruplicate. ** p < 0.001. (b) Ampk+/+ (Ampk+/+) and Ampk-/- MEFs (Ampk-/-) expressing (Mct4+/+) 
or not (Mct4-/-) MCT4 incubated in normoxia (Nx) or hypoxia 1% O2 (Hx) for 48h in the absence or the presence (+ MCTi, 300 nM) of MCT 
inhibitor. Cell mortality (%) was evaluated by Trypan blue exclusion. The mean±S.E.M. is representative of three independent experiments 
carried out in duplicate. (c) In vitro exponential growth of Ampk+/+ (Ampk+/+) and Ampk-/- MEFs (Ampk-/-) expressing (Mct4+/+) or not (Mct4-
/-) MCT4 incubated up to 72 h in normoxia (Nx – top panel) or hypoxia 1% O2 (Hx – bottom panel) in the absence or the presence of the 
MCT inhibitor (+ MCTi, 300 nM). The mean±S.E.M. is representative of three independent experiments carried out in duplicate. (d) Clonal 
growth in normoxia (Nx) of Ampk+/+ (Ampk+/+) and Ampk-/- (Ampk-/-) MEFs expressing (Mct4+/+) or not (Mct4-/-) MCT4, in the absence or 
presence of the MCT inhibitor (+ MCTi, 300 nM) for 8 days before staining and visualization of the colonies. (e) Clonal growth in hypoxia 
1% O2 (Hx) of Ampk
+/+ (Ampk+/+) and Ampk-/- (Ampk-/-) MEFs expressing (Mct4+/+) or not (Mct4-/-) MCT4, in the absence or presence of the 
MCT inhibitor (+ MCTi) for 8 days before staining for visualization of the colonies. 
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expressing MCT4 (Ampk+/+Mct4+/+ et Ampk-/- Mct4+/+) 
(Figure 3c). When Mct4 was knocked out, inhibition of 
MCT1 greatly reduced proliferation at 48h (Ampk+/+Mct4-/- 
ou Ampk-/- Mct4-/-) but less in MEFs that did not express 
functional AMPK. At 72h, both inhibition of MCT1 
and knockout of MCT4 led to a stronger inhibition of 
proliferation in Ampk+/+ in normoxia (76%±0.6%) than 
that in Ampk-/- MEFs (32%±3%). In hypoxia, Ampk+/+ 
and Ampk-/- MEFs proliferated more slowly than that in 
normoxia and MCT1 inhibition had no significant effect 
on these cells (Figure 3c). In contrast, MCTi inhibited 
proliferation of Mct4-deficient cells, in a manner 
similar to that of Ampk+/+Mct4-/- MEFs (75%±0.6%) 
and Ampk+/+Mct4-/- MEFs (62%±0.8%) (Figure 3c and 
Supplementary Figure 3c). Cell growth and/or mortality 
over a long period of time in normoxia (Figure 3d and 
Supplementary Figure 3d) and in hypoxia (Figure 3e 
and Supplementary Figure 3e) were determined by the 
clonogenicity assay. Proliferation was strongly reduced in 
Ampk+/+Mct4-/- or Ampk-/- Mct4+/+ MEFs in the presence of 
MCTi in both conditions.
Although small differences between Ampk+/+ 
and Ampk -/- MEFs were found, all these results suggest 
that after blockade of lactate export and inhibition of 
glycolysis, MEFs did not require the presence of AMPK 
to maintain a viable level of ATP in vitro.
AMPK did not confer a survival benefit following 
the combined blockade of glycolysis and 
respiration, but induced resistance to glucose 
deprivation
Ampk+/+ and Ampk-/- MEFs expressing MCT4 
(Mct4+/+) or not (Mct4-/-) were treated in hypoxia with 
MCTi combined with phenformin (MCTi/Phenf) an 
inhibitor of mitochondrial respiratory chain complex 
1. Combination of MCTi/Phenf did not alter ATP levels 
in MEF expressing MCT4 (Ampk+/+ Mct4+/+ et Ampk-/- 
Mct4+/+ MEFs) (Figure 4a, left panel). In Ampk+/+ Mct4-
/- MEFs, while phenformin alone did not affect the level 
of ATP (Supplementary Figure 4a) the combination of 
MCTi/Phenf gradually reduced the ATP pool from 97%±1, 
60%±1 and 25%±3 of its initial level after 8, 24 and 48h of 
treatment, respectively (Figure 4a, left panel). A reduction 
in the ATP level in the Ampk-/- Mct4-/- MEFs was similar to 
that of Ampk+/+ Mct4-/- MEFs. No difference in mortality 
was observed between Ampk+/+ Mct4+/+ or Ampk-/- Mct4+/+ 
MEFs (Figure 4a, right panel). However, for Ampk+/+ Mct4-
/- and Ampk-/- Mct4-/- MEFs 27%±3% and 36%±4% cell 
mortality was observed, respectively. Similar results were 
obtained when ATP was collapsed with the MCTi/Oligo 
combination (Supplementary Figure 4b). Phenformin 
slowed cell proliferation in a similar manner: 34%±1% 
(Ampk+/+ Mct4+/+), 39%±4% (Ampk+/+Mct4-/-), 30%±6% 
(Ampk-/-Mct4+/+) and 28%±3.8% (Ampk-/- Mct4-/-) (Figure 
4b) without affecting cell viability (data not shown). 
Combination of MCTi/Phenf decreased slightly the cell 
number over 72 h in a similar manner in Ampk+/+ Mct4+/+ 
(28%±1) and Ampk-/-Mct4+/+ (33%±2) MEFs (Figure 4B). 
However, the cell number was significantly reduced by 
94%±2% in Ampk+/+Mct4-/- MEFs and by 91%±2% in 
Ampk+/+Mct4-/- MEFs after 72 h of MCTi/Phenf treatment. 
The same effect was observed after 8 days of growth using 
the clonogenicity assay (Supplementary Figure 4c). 
Taken together these results showed that 
MCT4 knockout sensitized MEFs to the MCTi/Phenf 
combination, which reduced substantially the ATP level, 
viability and proliferation. Knockout of AMPK was 
neither beneficial nor unfavourable to these parameters. 
The question then was whether AMPK provides an 
advantage in cell survival in response to a rapid decrease in 
the level of ATP. The MCTi/Phenf combination impacted 
on the ATP levels after 24h of treatment (Figure 4a). As 
oligomycin rapidly blocked production of ATP in contrast 
to phenformin, it was added in the presence of decreasing 
concentrations of glucose (10 mM, 1mM or 0.1 mM) 
(Figure 4c). In the presence of 10mM glucose oligomycin 
dropped the level of ATP (49%±6%) in 10min either in 
the Ampk+/+ or Ampk-/- MEFs,. This level was gradually 
restored, and even reached values  above the basal level 
of ATP 1h after treatment (Figure 4c, top panel). When 
oligomycin was added to medium containing 1mM 
glucose, ATP levels dropped rapidly to similar levels to 
those in the presence of 10 mM glucose (49%±3% and 
38%±2% for Ampk+/+ or Ampk-/- MEFs, respectively) 
(Figure 4c, middle panel). However, none of these two 
populations of MEFs completely restored their basal 
level of ATP. When oligomycin was added to medium 
containing 0.1mM glucose, a significant difference was 
observed between levels of ATP for Ampk+/+ compared 
to Ampk-/- MEFs, 28%±3% versus 9%±2%, respectively 
(Figure 4c, bottom panel). This difference was amplified 
after 1h of treatment as Ampk+/+ MEFs had an ATP level 
of 63%±0.5% compared to Ampk-/- MEFs (28%±3%). 
In the absence of 10 mM glucose±2-deoxy-glucose, 
oligomycin collapsed ATP production, independently of 
the AMPK activity (Supplementary Figure 4d and 4e). 
Little difference in cell number was observed between 
Ampk+/+and Ampk-/- MEFs in the presence of 25 mM 
glucose (Figure 4d). However, in the presence of 0.1 or 
1mM glucose, proliferation of Ampk+/+ MEFs slowed 
while a decrease in the glucose concentration dramatically 
impacted cell viability of Ampk-/- MEFs. 
Taken together these results suggest that AMPK is 
not required to maintain a viable level of ATP in response 
to inhibition of glycolysis via blockade of MCTs or 
metabolic shock (MCTi/Phenf). The only differences 
observed were obtained under conditions of low glucose 
concentrations (0.1 and 1 mM).
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Figure 4: AMPK is not sufficient to guaranty viability in response to inhibition of MCT1 (MCTi) and MCT4 (Mct4-/-) 
inhibition combined with phenformin (Phenf), but is important to promote cell survival following a nutritive stress. (a) 
Left panel - Total cellular ATP level in Ampk+/+ (Ampk+/+) and Ampk-/- (Ampk-/-) MEFs expressing (Mct4+/+) or not (Mct4-/-) MCT4 incubated 
in hypoxia 1% O2 (Hx) for up to 48 h in the presence of a combination with MCTi (300 nM) and phenformine (50 µM) (+ MCTi/Phenf), 
standardized to the protein content for each condition and normalized to initial cellular ATP level (%). The mean±S.E.M. is representative 
of three independent experiments carried out in quadruplicate. Right panel –Ampk+/+ (Ampk+/+) and Ampk-/- (Ampk-/-) MEFs in the presence 
(black signs in bars) or absence (grey signs in bars) of Mct4 (± Mct4) were incubated in normoxia (Nx) for 48 h with the MCTi/Phenf 
combination, 300 nM and 50µM respectively. Cell mortality (%) was evaluated with the automatic cell counter ADAM. The mean±S.E.M. 
is representative of three independent experiments carried out in triplicate. (b) In vitro exponential growth of Ampk+/+ (Ampk+/+) and Ampk-
/- MEFs (Ampk-/-) expressing (Mct4+/+) or not (Mct4-/-) MCT4 incubated for up to 72 h in hypoxia 1% O2 (Hx) in the absence or presence of 
phenformine (+ Phenf) or presence of the MCTi/Phenf combination (+ MCTi/Phenf), 300 nM and 50 µM respectively. The mean±S.E.M. 
is representative of three independent experiments carried out in duplicate. (c) Total cellular ATP level in Ampk+/+ (Ampk+/+) and Ampk-
/- (Ampk-/-) MEFs expressing MCT4 (Mct4+/+) incubated in normoxia (Nx) in 10-, 1- and 0.1-mM glucose, in the presence of oligomycine 
(Oligo, 1 µM) for up to 180min, standardized to the cell protein content for each condition and normalized to initial cellular ATP level (%). 
The mean±S.E.M. is representative of three independent experiments carried out in triplicate. The mean±S.E.M. is representative of two 
independent experiments carried out in quadruplicate. * p < 0.005, ** p < 0.001. (d) Clonal growth in normoxia (Nx) of Ampk+/+ (Ampk+/+) 
and Ampk-/- (Ampk-/-) MEFs expressing MCT4 (Mct4+/+) in 10-, 1- and 0.1-mM glucose for 3 days then incubated for 10 days in 25 mM 
glucose before staining for visualization of the colonies.
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Knockout of AMPK or Mct4 or both strongly 
impact on the tumourigenicity
We then investigated the behaviour of these cells in 
a tumour context. Ampk+/+ Mct4+/+ control MEFs showed 
rapid tumour growth, up to 200mm3 after 12 days (±3) and 
greater than 1000mm3 after 21 days of injection (Figure 
5a). We observed a high latency in tumour growth with 
Ampk-/-Mct4+/+ MEFs as the tumours reached 200mm3 after 
44 days (±6) post-injection. However, after this period, 
the rate of tumour growth was identical for Ampk+/+ and 
Ampk-/- MEFs (Figure 5a). Moreover, Ampk+/+Mct4-/- MEF 
showed slowed tumourigenicity but not tumour growth 
as Ampk+/+ Mct4-/- MEFs exhibited a tumour volume of 
200mm3 to 1000mm3 in 33 days (±6) and 40 days (±6), 
respectively (Figure 5a). Ampk-/- Mct4-/- MEF-derived 
tumours grew much slower (Figure 5a). The absence of 
AMPK activity in MEF-derived tumuors was confirmed 
(Figure 5b). 
These results clearly show that independently 
AMPK and MCT4 impact on tumour development but 
when taken together the in vivo consequence is reinforced.
DIscUssION
AMPK is widely recognized as the guardian 
of the balance in energy and as a critical regulator of 
intracellular ATP level. However, in the present study, we 
showed for the first time, that AMPK was dispensable for 
maintenance of the ATP level and viability of fibroblasts 
when glycolysis was limited by MCT blockade. However, 
we confirmed that Ampk-/- MEFs were more sensitive to 
glucose deprivation or to acute energy stress than their 
wild type counterpart. While the double knockout of 
AMPK and MCT4 (Ampk-/- Mct4-/-) did not drastically 
change the ATP level or the characteristics of growth in 
vitro, it showed a marked decrease in the tumour incidence. 
These results lead us to ask the following questions: (i) 
What are the differences, from an energy point of view, 
between inhibiting glycolysis by restricting lactic acid 
export versus decreasing availability of glucose? (ii) Is 
AMPK a tumour suppressor or an oncogene in our model? 
(iii) Why did the double knockout of AMPK and MCT4 
reduce substantially tumourigenicity while no phenotypic 
differences were found in vitro?
Our approach to reducing tumour growth by 
blocking the last step of fermentative glycolysis (export of 
lactic acid) [15] was recently confirmed in and extended to 
other cancer cell lines [17, 25, 26, 47]. Although blockade 
of glycolysis was capable of restricting proliferation, 
intracellular ATP levels and cell viability were maintained 
due to re-activation of OXPHOS. Indeed discontinuation 
of MCTi treatment restored tumour growth indicating a 
cytostatic effect [15, 8]. The aim of this study was to test 
the hypothesis that combining inhibition of glycolysis 
with suppression of AMPK should induce acute tumour 
cell death from ‘ATP crisis’. In the absence of a specific 
inhibitor of AMPK, we used Ras-transformed MEFs 
knocked out for the two isoforms of AMPK, α1 and α 2 
[44].
Differences in blockade in energy. We showed that 
pharmacological inhibition of MCT1 in Mct4-/- MEFs 
in normoxia rapidly led to inhibition of glycolysis, 
which induced a stress in energy as observed from the 
activation of AMPK in Ampk+/+ MEFs (Figure 2f). In this 
circumstance, deletion of AMPK did not affect either ATP 
levels (Figure 3a) or the rate of proliferation (Figure 3c) in 
response to energy stress suggesting that MEFs adjust their 
energetic homeostasis independently of AMPK. However, 
a beneficial effect of AMPK in cell survival was evident 
when MEFs were subjected to limiting concentrations of 
glucose. Why such a difference? Our main hypothesis 
to explain this phenomenon lies in the inhibitory effect 
of pHi on protein synthesis and proliferation. Indeed, 
inhibition of MCTs is associated with intracellular 
acidification [15, 17]. However, intracellular acidosis, 
in addition to reducing the glycolytic flux through the 
inhibition of hexokinase or phosphofructokinase [48-50] 
leads to inhibition of mTORC [51-53], one of the most 
energy-demanding anabolic pathways [54]. Therefore, we 
proposed that intracellular acidification resulting from our 
anti-MCT strategy mimicked the action of AMPK under 
conditions of energy stress: inhibition of mTORC1 and 
presumably other anabolic pathways. Two recent studies 
showing that mTORC1 may be inhibited in response to 
energy stress through a mechanism that does not involve 
AMPK [55, 56], support our hypothesis. In contrast, when 
the glucose concentration was reduced from 10 to 1mM, a 
significant decrease in the rate of glycolysis was observed. 
Moreover, suppression of glycolysis was reached at 
0.3mM glucose. Under these conditions cellular growth 
stopped and MEFs maintained their ATP levels through 
OXPHOS using glutamine and residual glucose. Thereby, 
AMPK facilitated cell survival by supporting energy 
reprogramming through blockade of anabolic pathways. 
These more pathophysiological conditions of energy stress 
obtain by a gradual deficiency in glucose allow a better 
understanding of the beneficial effect on survival of cells 
expressing AMPK.
It is now well established that glycolysis is closely 
linked to cell proliferation [2, 57]. Differentiated cells 
and cells with a low proliferative rate depend almost 
exclusively on cellular respiration to produce cellular 
ATP. To counteract this metabolic reprogramming, 
we combined inhibition of mitochondrial respiration 
(oligomycin or phenformin) with inhibition of glycolysis. 
The conclusion regarding the benefit of AMPK in these 
conditions seems to depend on the intensity/kinetics of 
the imposed “metabolic block”. Indeed, the MCTi/Phenf 
combination, by gradually decreasing the ATP pool, 
affected similarly Ampk+/+ and Ampk-/- MEFs (Figure 4a). 
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However, the MCTi/Oligo combination, which affected 
more rapidly ATP levels than the previous combination, 
had a stronger effect on ATP levels in Ampk-/- MEFs after 
24 or 48 h of treatment (Supplementary Figure 4b). In 
conclusion, the apparent role of AMPK in regulating the 
level of ATP is mainly highlighted when glycolysis is 
inhibited by a gradual reduction in the concentration of its 
critical substrate, glucose (Figure 4c).
AMPK and tumour development. The role of 
AMPK in cancer is controversial [58]. AMPK is both a 
tumour suppressor, responsible for a cytostatic effect when 
activated, and a protector of tumour cells, allowing them 
to survive in a hostile environment for extended periods 
of time, which occurrs during development of solid 
tumours [59, 60]. In our study, we observed a strong delay 
in tumour establishment of Ampk-/- MEFs compared to 
Ampk+/+ MEFs. This tumour growth delay, also described 
by Laderoute et al. [44], confered to AMPK a protective 
or a pro-tumoural role. However, when tumour growth 
was initiated, the rates of tumour growth of Ampk+/+ and 
Ampk-/- MEFs were similar, which is not in favour of an 
“oncogene” function. We propose that the delay observed 
at the time of tumour establishment would reflect a 
much higher sensitivity of Ampk-/- MEFs to the poorly 
vascularised microenvironment, which is low in oxygen 
and glucose. Results reported in figure 4d reinforce this 
hypothesis. Indeed, they showed that Ampk-/- MEFs are 
particularly sensitive to a decrease in glucose availability, 
Figure 5: Dual knockout of Ampk (Ampk-/-) and Mct4 (Mct4-/-) dramatically decreased xenograft tumour development. 
(a) In vivo xenograft assays were performed by injecting s.c. into the back of athymic nude mice 1x106 viable and individual tumour 
Ampk+/+ (Ampk+/+) or Ampk-/- (Ampk-/-) MEFs expressing (Mct4+/+) or not (Mct4-/-) MCT4. Xenograft growth was determined by measuring 
the tumour volume. In vivo experiments were repeated twice. Five mice were studied per condition. (b) Immunohistological confirmation 
of the expression of Phospho-AMPK (P-AMPK) and Phospho-ACC (P-ACC) in the corresponding Ampk+/+ and Ampk-/- tumour xenografts 
(Magnification: 20×).
Oncotarget11843www.impactjournals.com/oncotarget
an omnipresent feature during the initiation phase of solid 
tumour establishment. Moreover, Faubert et al. showed 
accelerated development of lymphomas in transgenic 
Ampkα1 knockout mice (single subunit expressed in B 
cells) overexpressing c-Myc [61]. This result is consistent 
with the normal tumour growth rate observed for Ampk-/- 
MEFs after tumour establishment. However, the question 
of the role of AMPK in initiating solid tumours remains 
open. Indeed, both models developped by Faubert or our 
selves failed to clearly define the positive or negative effect 
of AMPK during establishment of solid tumour. However, 
we provided additional evidence that AMPK is not a key 
oncogene in tumour growth after their establishment. In 
contrast to Li et al. [62] or Zhou et al. in [63] who studied 
ovarian and prostate cancer, respectively, loss of AMPK 
did not promote tumour growth in Ras-transformed MEFs.
MCT4 and AMPK, a dynamic duo for tumour 
growth. In contrast to studies that have largely focused 
on MCT1 [25, 47, 64], our team has developed the 
notion that dual blockade of MCT1 and MCT4 is critical 
to arrest glycolytic tumour growth [15, 17, 26]. Here 
we showed that Mct4 knockout alone severely affected 
tumour establishment of both Ampk+/+ and Ampk-/- MEFs 
in subcutaneous xenografts. However, it did not affect 
the tumour growth rate suggesting that in this cellular 
setting MCT1 did not ensure sufficient export of lactate 
on its own. It also established that the function “lactate 
transport” is crucial when establishing solid tumours, at 
least in the model of murine tumour xenografts. These 
results are consistent with those obtained with the Ras-
transformed fibroblast CCL39-derived mutants impaired 
in mitochondrial respiration [65] and expressing MCT1 
and not MCT4 [15]. These respiratory-deficient CCL39-
derived mutants showed reduced tumour incidence 
(20%), whereas ectopic expression of MCT4 was 
sufficient to restore full tumourigenicity (100%)[15]. 
Forced expression of MCT4 in these cells induced a more 
alkaline cytoplasmic pH with concomitant activation of 
glycolysis[66]. 
Our study showed that Mct4 knockout in a Ampk-
/- context severely affected both tumour establishment 
and tumourigenicity, demonstrating an important role 
for AMPK and MCT4 in tumour development. How do 
we explain the effect of Ampk/Mct4 double-knockout 
on tumourigenicity when we observed no or little 
phenotypic differences of these cells in vitro, compared 
to single Ampk-/- MEF knockout? Could MCT4 be 
involved specifically in proliferation in a 3D context, in 
angiogenesis, or in metabolic interactions with the tumour 
microenvironment? A recent study demonstrated that 
Mct4 knockdown by shRNA reduced both the stem cell 
population (CD133+) and the glioblastoma tumour growth 
by an unknown mechanism, independently of its function 
of lactate transporter [67]. Such an unknown mechanism 
could be involved in the absence of development of Mct4-
/- tumours. Moreover, the absence of AMPK could also 
amplify this phenomenum. 
Molecules targeting MCT4 are currently under 
development, and our in vivo results suggest that these 
molecules could have some therapeutic interest in the 
context of restricted AMPK activity. Unfortunately, 
currently there is no specific inhibitor of AMPK. However, 
as LKB1, the upstream kinase of AMPK, has been found 
to be mutated in several tumour types [68], one could 
consider that these cancers have a deficiency in the AMPK 
activity. Targeting MCT4 in these tumours is an attractive 
therapeutic opportunity worth investigation . 
Finally, this study revealed that the bioenergetic 
plasticity in regulation of glycolysis and OXPHOS could 
occur in AMPK-null cells. We propose that intracellular 
acidification resulting from lactic acid sequestration 
mimicks AMPK by blocking mTORC1, a major ATP 
consuming pathway, therefore preventing killing by 
‘ATP crisis’. In line with cell killing we are left with the 
option of targeting MCTs with acute treatment with the 
anti-diabetic drug phenformin [17, 26, 27]. Paradoxically 
phenformin is an activator of AMPK but, as shown here, it 
kills cells treated with MCTi independently of the AMPK 
status and via inhibition of mitochondrial complex I. 
MAtErIALs AND MEtHODs 
cell culture
Wild-type (Ampk+/+) and double knockout for 
Ampkα1 and Ampkα2 (Ampk-/-) murine embryonic 
fibroblasts (MEFs), were previously described[44] and 
were kindly provided by Dr B.Viollet (Institut Cochin, 
Paris, France). They were transformed (Retroviruses 
– System Phoenix) with the oncogene RasV12 (plasmid 
#1768 from Addgene) following the Retrovirus Production 
and Infection from the Rockefeller University protocols. 
MEFs and the human colon carcinoma LS174 cell line 
were grown in Dulbecco’s modified Eagle’s medium 
(DMEM) (Gibco-BRL) supplemented with 10% foetal 
bovine serum (FBS). LS174-Mct4-/- were previously 
described [15]. Penicillin G (50 U/ml) and streptomycin 
sulfate (50 µg/ml) were added. When experiments were 
performed with medium containing 0.1 or 1mM glucose, 
medium was changed every 24 h to minimize variations in 
the glucose concentration in the medium during the time 
of the experiment. 
For hypoxic cultures the Bug-BoxTM anaerobic 
workstation (Ruskinn Technology Biotrace International 
Plc, Bridgend, UK) was set at 1% or 0.1% oxygen, 94% 
or 94.9% nitrogen, respectively and 5% carbon dioxide 
was used.
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Nude mice tumourigenicity and 
immunohistochemistry
This study was carried out in strict accordance with 
the recommendations in the Guide for the Care and Use of 
Laboratory Animals of Centre National de la Recherche 
Scientifique (CNRS). All efforts were made to minimize 
suffering. Our experiments were approved by the 
‘‘Comité national institutionnel d’éthique pour l’animal 
de laboratoire (CIEPAL)’’. The project is registered under 
the reference: NCE/-165. 
ZFN-mediated gene knockout of the mct4 gene, 
Colony-forming assay, Proliferation and Cell survival 
Assay, Immunoblot analysis, Metabolic measurements, 
ATP determination, Glucose consumption and Lactate 
measurement. The corresponding methodology is given 
in the supplemental data.
statistics
All values are the means ± SD of the indicate 
number of determinations (n) and significant differences 
are based on the Student’s t-test and P values indicated (*P 
< 0.05, **P < 0.01).
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